Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

SLC33A1 Gene (SPG42) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين SLC33A1 (SPG42) بتقنية التسلسل الجيني المتقدم في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

  • Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).
  • Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM daily).
  • Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation included, delivered by a DHA-licensed neurologist.
  • Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731 (24/7 automated check).

ملخص تنفيذي

يتم إجراء تحليل جين SLC33A1 (SPG42) تحت إشراف هيئة الصحة بدبي، مع ضمان دقة تشخيصية تصل إلى 99.9% باستخدام منصة التسلسل الجيني المتقدم المعتمدة ISO 9001:2015، وخدمة سحب منزلي بمعايير سلسلة التبريد الدولية، واستشارة هاتفية بعد النتائج مع أطباء الأعصاب.

Test Overview & Clinical Utility

Clinical Summary: This test screens the SLC33A1 gene for pathogenic variants causing hereditary spastic paraplegia type 42 (SPG42), a rare neurodegenerative disorder presenting with progressive leg weakness and spasticity. Using Next‑Generation Sequencing (NGS), every coding exon is analyzed with bioinformatic pipelines validated against ACMG guidelines.

يكشف هذا الفحص الطفرات الجينية في جين SLC33A1 المسبب للشلل النصفي التشنجي الوراثي من النوع 42، عبر تقنية التسلسل الجيني المتقدم.

Targeted Specialists

  • Neurologist – diagnostic workup of spastic paraplegia
  • Clinical Geneticist – family risk stratification and counselling
  • At-Risk Individuals – proactive genetic insight (peace of mind)
Feature Our 2026 NGS Test Closest Alternative (Single‑Gene Sanger)
Precision 99.9% analytical sensitivity / specificity ~95% for targeted regions only
Method NGS (Illumina NovaSeq) + CNV calling Sanger sequencing, limited to a few exons
Turnaround 3–4 weeks (with interim report option) 6–8 weeks

Physician Insight & Safety Protocol

“A positive result on this SLC33A1 test does not, in itself, confirm a definitive diagnosis; it must be interpreted within the context of your full clinical picture, imaging findings, and family history. Our team will guide you through a post‑test consultation to ensure you understand the implications for treatment, surveillance, and family planning.”

— Dr. PRABHAKAR REDDY, DHA License 61713011

⚕️ CLINICAL NOTICE: Do not discontinue any prescribed medication or alter your neurological therapy plan without prior consultation with your treating physician. Genetic test results are not a substitute for continuous medical supervision.

🛑 Exclusion Criteria & ER Red Flags

  • Sample Exclusion: Samples with EDTA tubes past expiry, gross hemolysis, or microbial contamination will be rejected.
  • Patient Ineligibility: Individuals unable to provide valid informed consent or a complete clinical history; minors must have legal guardian consent per UAE CDS Law 2026.
  • Emergency Red Flags: If you experience sudden loss of ability to walk, severe muscle rigidity with fever, or breathing difficulties, call 998 (UAE Ambulance) immediately. These symptoms require urgent neurological assessment and are not addressed by a scheduled genetic test.

Patient FAQ & Clinical Guidance

What is the SLC33A1 (SPG42) genetic test?

ما هو تحليل جين SLC33A1 (SPG42)؟

The SLC33A1 gene analysis uses next-generation sequencing to identify mutations causing hereditary spastic paraplegia SPG42. This test examines all coding regions and exon–intron boundaries of the SLC33A1 gene, providing a definitive genetic diagnosis for SPG42-associated neurodegenerative disease. Results are interpreted according to ACMG/AMP 2026 variant classification standards, and a board‑certified clinical geneticist reviews each case.

تحليل جين SLC33A1 باستخدام التسلسل الجيني المتقدم يكشف الطفرات المسببة للشلل النصفي التشنجي الوراثي SPG42. يفحص الفحص جميع مناطق الجين ويقدم تفسيراً معتمداً من هيئة الصحة بدبي.

Who should consider this genetic?

من هم الأشخاص الذين ينبغي عليهم إجراء هذا الفحص الجيني؟

Those with progressive spastic paraplegia family history or unexplained neurological symptoms should consider genetic testing. This includes individuals with gait disturbances, muscle stiffness, or hyperreflexia of unknown cause, as well as asymptomatic relatives of a known SPG42 patient. Genetic counselling is mandatory prior to testing and is integrated into our service pathway.

الأشخاص الذين لديهم أعراض شلل نصفي تشنجي غير مفسرة أو تاريخ عائلي للمرض يجب عليهم التفكير في الفحص الجيني، ويشمل ذلك الأقارب غير المصابين بعد استشارة وراثية.

How is the sample collected and what is the turnaround time?

كيف يتم جمع العينة وما هي مدة الحصول على النتائج؟

A home blood draw or FTA card yields genetic results within three to four weeks. Our VIP mobile phlebotomy team arrives at your doorstep between 8 AM and 11 PM, using either a standard EDTA tube for whole blood or a simple finger‑prick onto an FTA card. The sample is transported in an ISO‑certified cold chain, and you will receive a secure PDF report with an optional tele‑consultation.

يتم جمع العينة منزلياً عبر سحب دم أو بطاقة FTA، وتظهر النتائج خلال 3 إلى 4 أسابيع مع خدمة سلسلة تبريد معتمدة واستشارة هاتفية.

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians